Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab

Ann Hematol. 2017 Dec;96(12):2117-2119. doi: 10.1007/s00277-017-3111-x. Epub 2017 Sep 1.

Authors

Mitsuhiro Akiyama¹, Hidekata Yasuoka¹, Tsutomu Takeuchi²

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
² Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan. tsutake@z5.keio.jp.

PMID: 28861599
DOI: 10.1007/s00277-017-3111-x

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Biomarkers
Castleman Disease / blood*
Castleman Disease / drug therapy
Drug Administration Schedule
Female
Humans
Interleukin-6 / blood*
Male
Middle Aged
Receptors, Interleukin-6 / antagonists & inhibitors
Receptors, Interleukin-6 / immunology
Recurrence

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
IL6 protein, human
Interleukin-6
Receptors, Interleukin-6
tocilizumab